<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02346539</url>
  </required_header>
  <id_info>
    <org_study_id>2014P002495-01</org_study_id>
    <secondary_id>5K01DA029645-04</secondary_id>
    <nct_id>NCT02346539</nct_id>
  </id_info>
  <brief_title>Effect of Nicotine on Brain Reward Pathways</brief_title>
  <official_title>Effect of Nicotine on Brain Reward Pathways</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mclean Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute on Drug Abuse (NIDA)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Mclean Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The investigators will determine whether an acute dose of nicotine, in the form of the
      nicotine lozenge, impacts brain and behavioral measures of mood and reward responsiveness in
      individuals with major depressive disorder.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>February 2015</start_date>
  <completion_date type="Actual">November 2017</completion_date>
  <primary_completion_date type="Actual">November 2017</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from Placebo in functional magnetic resonance imaging (fMRI) BOLD Response</measure>
    <time_frame>Participants will be assessed during 2 fMRI scanning sessions, an expected average of 2 weeks.</time_frame>
    <description>Nicotine will enhance the fMRI BOLD response to monetary reinforcers relative to placebo administration</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">46</enrollment>
  <condition>Depressive Disorder</condition>
  <arm_group>
    <arm_group_label>Nicotine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>2mg of nicotine in the form of a nicotine polacrilex lozenge will be administered orally, one time.
4mg of nicotine in the form of a nicotine polacrilex lozenge will be administered orally, one time.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo comparator</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nicotine polacrilex</intervention_name>
    <description>Single Acute dose</description>
    <arm_group_label>Nicotine</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>Nicotine lozenge</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria for subjects with Major Depressive Disorder:

          1. Provide written informed consent;

          2. Both genders and all ethnic origins, age between 18 and 45;

          3. Meet DSM-IV diagnostic criteria for MDD (diagnosed with the use of the SCID);

          4. A baseline HAM-D score of 16 or greater;

          5. Absence of pregnancy;

          6. Absence of any psychotropic medication for at least 2 weeks:

               1. 6 weeks for fluoxetine

               2. 6 months for neuroleptics

               3. 2 weeks for benzodiazepines

               4. 2 weeks for any other antidepressants

        Inclusion Criteria for Healthy Controls

          1. Absence of medical, neurological, and psychiatric illness (including alcohol and
             substance abuse); as assessed by subject history and a structured clinical interview
             (SCID);

          2. Provide written informed consent;

          3. Both genders and all ethnic origins, age between 18 and 45;

          4. Absence of any medications for at least 3 weeks;

          5. Absence of pregnancy.

        Exclusion Criteria:

          1. Subjects with suicidal ideation where outpatient treatment is determined unsafe. These
             patients will be immediately referred to a licensed psychologist or psychiatrist to
             determine the appropriate clinical treatment;

          2. Serious or unstable medical illness

          3. Lifetime history of seizure disorder;

          4. Lifetime history or current diagnosis of any of the following DSM-IV psychiatric
             illnesses: organic mental disorder, schizophrenia, schizoaffective disorder,
             delusional disorder, psychotic disorders not otherwise specified, bipolar disorder,
             ADHD, patients with mood congruent or mood incongruent psychotic features; simple
             phobia, social anxiety disorder and generalized anxiety disorders will be allowed only
             if secondary to MDD;

          5. Patients with a lifetime history of electroconvulsive therapy (ECT);

          6. Failure to meet standard MRI safety requirements;

          7. May not have used any nicotine product in the past year; must report fewer than 20
             lifetime uses of nicotine

          8. Must have an expired carbon monoxide level of less than or equal to 10 ppm.

          9. Use of anticholinergic drugs in the past week

         10. Any past or present history of cardiac problems including known arrhythmias, acute
             coronary syndrome, or ischemic heart disease

         11. Uncontrolled hypertension

         12. History of substance abuse in the past 6 months (other than caffeine), self-reported
             use of marijuana in past month, or history of treatment with methadone

         13. Heavy caffeine users (consume greater than 500 mg on a regular or daily basis)

         14. Subjects that cannot speak English
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Amy Janes, Ph.D</last_name>
    <role>Principal Investigator</role>
    <affiliation>Mclean Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>McLean Hospital</name>
      <address>
        <city>Belmont</city>
        <state>Massachusetts</state>
        <zip>02478</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 14, 2015</study_first_submitted>
  <study_first_submitted_qc>January 20, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 27, 2015</study_first_posted>
  <last_update_submitted>March 21, 2018</last_update_submitted>
  <last_update_submitted_qc>March 21, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 22, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Mclean Hospital</investigator_affiliation>
    <investigator_full_name>Amy C. Janes</investigator_full_name>
    <investigator_title>Assistant Professor/Neuroscientist</investigator_title>
  </responsible_party>
  <keyword>Nicotine</keyword>
  <keyword>Depression</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Depressive Disorder</mesh_term>
    <mesh_term>Depression</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nicotine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

